Prostate News Archive
24-Feb-2009
Enough is Enough of Prostate-Specific-Antigen Testing Once Men Reach Age 75 (Senior Journal)
Feb. 23, 2009 - Although widespread prostate-Specific-Antigen (PSA) testing has undoubtedly decreased prostate cancer mortality, there appears to be a point of diminishing returns? GTx Initiates Phase I Clinical Trial for GTx-758, an Oral Luteinizing Hormone Inhibitor for Advanced Prostate Cancer (Centre Daily Times)
GTx, Inc. (NASDAQ: GTXI) announced today that it has initiated a Phase I clinical trial for GTx-758, an oral luteinizing hormone (LH) inhibitor to treat men with advanced prostate cancer. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758 using a single ascending dose, double blind, placebo controlled design in healthy male volunteers. GTx Initiates Phase I Clinical Trial for GTx-758, an Oral Luteinizing Hormone Inhibitor for Advanced Prostate Cancer (Business Wire via Yahoo! Finance)
MEMPHIS, Tenn.----GTx, Inc. announced today that it has initiated a Phase I clinical trial for GTx-758, an oral luteinizing hormone inhibitor to treat men with advanced prostate cancer.
Back to Prostate News Archive
